Resources

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Myricx Bio is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.

September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.

The Milner Therapeutics Institute has been announced as a finalist for a 2025 OBN Award in the category of Most Impactful Industry Collaboration.

Pioneer Group has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.

In this blog, Paul Nelson, Corporate Foreign Exchange at Moneycorp, outlines the unpredictability of global markets and what this means for BIA members. 

Pharmaron is thrilled to announce the successful completion of Phase One in the major expansion of our Liverpool Gene Therapy and Biologics CDMO site!

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS), the experts in cellular starting materials providing donor material solutions to the cell and gene therapy industry.

MoU will explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

Arecor Therapeutics announces that it has concluded a positive Type C meeting with the US FDA for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.

MDC and King’s College London have been awarded £400,000 funding from The Brain Tumour Charity to develop a groundbreaking new approach to treat glioblastoma, for patient benefit.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

SeqOne, a pioneer in AI-driven genomic analysis, today announced it has entered into a definitive agreement to acquire Congenica, the UK company spun out of the prestigious Wellcome Sanger Institute.

Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.

In this blog, Alastair Hall, Hub Eurasia Director, FI Group, explores how Innovate UK Innovation Loans are helping biotech SMEs bridge the gap between research and commercialisation. He highlights why they are most effective when combined with other funding sources to build a resilient strategy for growth.

BIA member Charm Therapeutics, co-founded by Nobel laureate David Baker, has raised an $80 million Series B to move its AI-designed cancer drug into the clinic early next year.

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program.